Download PDF
CC BY-NC-ND 4.0 · Indian J Radiol Imaging 2017; 27(04): 427-431
DOI: 10.4103/ijri.IJRI_13_17
Paediatric

Intracranial translucency as a sonographic marker for detecting open spina bifida at 11–13+6 weeks scan: Our experience

Madhavi L Teegala
Department of Fetal Medicine, Rainbow Hospital, Vijayawada, Andhra Pradesh, India
,
Dhamangaonkar G Vinayak
Department of Fetal Medicine, Rainbow Hospitals, Kondapur, Hyderabad, Telangana, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
  PDF Download Permissions and Reprints

Abstract

Aims and Objectives: The fourth ventricle, seen as intracranial translucency (IT) at 11–13+6 weeks, has been reported to be obliterated in cases of open spina bifida (OSB). Our aim was to assess its role in detecting OSB at 11–13+6 weeks. Materials and Methods: This prospective study was conducted at foetal medicine unit from January 2014 to June 2015. All women who underwent both first and mid-trimester scan in our unit were included in the study. IT was categorized as normal, obliterated or not clear. Spine was examined during both scans. Results: Totally, 341 cases were included in the study. IT was found to be obliterated in four cases and not clear in one case. There was demonstrable OSB at 11–13+6 weeks in two cases, at 15–16 weeks in two cases and at 24 weeks in one case. In the remaining 336 cases with normal IT, spine was found to be normal at target scan. Conclusion: Mid-sagittal view of face that is routinely used to measure nuchal translucency (NT) can also be used to detect OSB. It is feasible to integrate IT into the routine 11–13+6 weeks scan.

Keywords

First trimester - intracranial translucency - open spina bifida


Publication History

Article published online:
27 July 2021

© 2017. Indian Radiological Association. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Flores AL, Vellozzi C, Valencia D, Sniezek J. Global burden of neural tube defects, risk factors, and prevention. Indian J Community Health 2014;26:3-5.
  • 2 Christianson AL. Medical genetics in primary health care. Indian J Pediatr 2000;67:831-5.
  • 3 Williams J, Mai CT, Mulinare J, Isenberg J, Flood TJ, Ethen M, et al. Updated estimates of neural tube defects prevented by mandatory folic acid fortification – United States, 1995–2011. MMWR Morb Mortal Wkly Rep 2015;64:1-5.
  • 4 Zaganjor I, Sekkarie A, Tsang BL, Williams J, Mulinare J, Razzaghi H, et al. Describing the prevalence of neural tube defects worldwide: A systematic literature review. PLoS One 2016;11:e0151586.
  • 5 Darmstadt GL, Howson CP, Walraven G, Armstrong RW, Kent A, Padilla CD, et al. Prevention of congenital disorders and care of affected children: A consensus statement. JAMA Pediatr 2016;170:790-3.
  • 6 Chaoui R, Benoit B, Mitkowska-Wozniak H, Heling KS, Nicolaides KH. Assessment of intracranial translucency (IT) in the detection of spina bifida at the 11–13-week scan. Ultrasound Obstet Gynecol 2009;34:249-52.
  • 7 Chaoui R, Nicolaides KH. From nuchal translucency to intracranial translucency: Towards the early detection of spina bifida. Ultrasound Obstet Gynecol 2010;35:133-8.
  • 8 Evans MI, Krantz DA, Hallahan TW, Sherwin J. Impact of nuchal translucency credentialing by the FMF, the NTQR or both on screening distributions and performance. Ultrasound Obstet Gynecol 2012;39:181-4.
  • 9 Sahota DS, Chen M, Leung TY, Fung TY, Ting YH, Lau TK, et al. Assessment of sonographer nuchal translucency measurement performance-central tendency and dispersion. J Matern Fetal Neonatal Med 2011;24:812-6.
  • 10 Sun Q, Xu J, Hu SQ, Chen M, Ma RM, Lau TK, et al. Distribution and normal reference range of fetal nuchal translucency thickness in Kunming pregnant women in the first trimester. Zhonghua Fu Chan Ke Za Zhi 2012;47:514-7.
  • 11 Christianson AL. Attaining human dignity for people with birth defects: A historical perspective. S Afr Med J 2013;103:1014-9.
  • 12 Penchaszadeh VB, Christianson AL, Giugliani R, Boulyjenkov V, Katz M. Services for the prevention and management of genetic disorders and birth defects in developing countries. Community Genet 1999;2:196-201.
  • 13 Sharma R. Birth defects in India: Hidden truth, need for urgent attention. Indian J Hum Genet 2013;19:125-9.
  • 14 Castillo Taucher S. Services for the care and prevention of birth defects. Reduced report of a World Health Organization and March of Dimes Foundation meeting. Rev Med Chil 2007;135:806-13.
  • 15 Gallagher PG. Diagnosis and management of rare congenital nonimmune hemolytic disease. Hematology Am Soc Hematol Educ Program 2015;2015:392-9.
  • 16 Nicolaides KH, Brizot ML, Snijders RJ. Fetal nuchal translucency: Ultrasound screening for fetal trisomy in the first trimester of pregnancy. Br J Obstet Gynaecol 1994;101:782-6.
  • 17 Nicolaides KH, Campbell S, Gabbe SG, Guidetti R. Ultrasound screening for spina bifida: Cranial and cerebellar signs. Lancet (London, England) 1986;2:72-4.
  • 18 Fong KW, Toi A, Okun N, Al-Shami E, Menezes RJ. Retrospective review of diagnostic performance of intracranial translucency in detection of open spina bifida at the 11-13-week scan. Ultrasound Obstet Gynecol 2011;38:630-4.